AU565Homo sapiens (Human)Cancer cell line

Also known as: AU 565, AU-565

🤖 AI SummaryBased on 12 publications

Quick Overview

Human breast cancer cell line with known genetic and molecular characteristics.

Detailed Summary

AU565 is a human breast cancer cell line derived from a pleural effusion of a patient with metastatic breast cancer. It is widely used in cancer research due to its well-characterized genetic and molecular features. The cell line exhibits specific mutations and gene expression profiles that make it a valuable model for studying breast cancer biology and therapeutic responses. AU565 has been utilized in various studies to investigate the mechanisms of cancer progression, drug sensitivity, and the role of specific genetic alterations in tumor development. Its use in research has contributed to the understanding of breast cancer heterogeneity and the identification of potential therapeutic targets.

Research Applications

Cancer biology researchDrug sensitivity studiesGenetic and molecular profilingTherapeutic target identification

Key Characteristics

Metastatic originWell-characterized genetic profileUsed in multiple studies for drug response analysis
Generated on 6/16/2025

Basic Information

Database IDCVCL_1074
SpeciesHomo sapiens (Human)
Tissue SourcePleural effusion[UBERON:UBERON_0000175]

Donor Information

Age43
Age CategoryAdult
SexFemale
Racecaucasian
Subtype FeaturesHER2+

Disease Information

DiseaseBreast adenocarcinoma
LineageBreast
SubtypeInvasive Breast Carcinoma
OncoTree CodeBRCA

DepMap Information

Source TypeATCC
Source IDACH-000248_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Arg175His (c.524G>A)UnspecifiedSomatic mutation acquired during proliferationfrom parent cell line YCC-3

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
12
D13S317
11,12
D16S539
9
D18S51
10,13
D19S433
14
D21S11
30,30.2
D2S1338
20,25
D3S1358
17
D5S818
9,12
D7S820
9,12
D8S1179
11,12
FGA
20
Penta D
9,12
Penta E
10,11
TH01
8,9
TPOX
8,11
vWA
17
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Enhancer transcription reveals subtype-specific gene expression programs controlling breast cancer pathogenesis.

Bedford M.T., Shi X.-B., Li W., Barton M.C., Dent S.Y.R., Kraus W.L.

Genome Res. 28:159-170(2018).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.

Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.

OncoImmunology 3:e954893.1-e954893.12(2014).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

Modeling precision treatment of breast cancer.";

Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.

Genome Biol. 14:R110.1-R110.14(2013).

Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target.

McCormick F., Gray J.W.

Cancer Cell 24:450-465(2013).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Breast cancer cell lines carry cell line-specific genomic alterations that are distinct from aberrations in breast cancer tissues: comparison of the CGH profiles between cancer cell lines and primary cancer tissues.

Yamamoto S., Oka M., Hirano T., Sasaki K.

BMC Cancer 10:15.1-15.10(2010).

The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression.

Petersen O.W., Gray J.W., Bissell M.J.

Mol. Oncol. 1:84-96(2007).

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.

Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.

Cancer Cell 10:515-527(2006).